BTK degradation by bexobrutideg suppresses B cell activation and FcεRI-mediated degranulation in preclinical models of chronic spontaneous urticaria By webmaster / May 14, 2026
Discovery and Characterization of CBL-B Intramolecular Glue Inhibitors That Increase T Cell Activation and Suppress Tumor Growth By webmaster / April 22, 2026
Combinatorial Optimization of Degrader-Antibody Conjugates Enabled by Automation By webmaster / April 2, 2026
Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial By webmaster / December 8, 2025
NX-1607: Translational Insights From a First-in-Human Study of an Oral CBL-B Inhibitor in Advanced Solid Tumors By AldenMC Production / November 7, 2025
Degrader Antibody Conjugates (DACs): Targeted Protein Degraders (TPDs) as Next Generation Antibody Drug Conjugate (ADC) Payloads By webmaster / October 29, 2025
NRX-0305: A Pan-Mutant Brain-Penetrant BRAF Degrader with Broad Preclinical Activity and Synergy with MEKi in Class 1/2/3 BRAF-Mutant Cancers By webmaster / September 23, 2025
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study By webmaster / July 16, 2025
